No­var­tis earns ad­com­m's vote of sup­port in come­back FDA re­view for En­tresto in sought-af­ter heart fail­ure pa­tients

5 years ago
Pharma
FDA+

Af­ter reel­ing back a gene ther­a­py from Sanofi, a North Car­oli­na up­start bags enough mon­ey to do some­thing about it

5 years ago
Financing
Cell/Gene Tx

Covid-19 roundup: It could be years be­fore vac­cines reach some coun­tries — re­port; EMA push­es up Pfiz­er vac­cine ...

5 years ago
Coronavirus

Up­dat­ed: Neu­ron23 launch­es with $113M fi­nanc­ing and eyes dead set on De­nali and Bio­gen

5 years ago
Financing
Startups

Trou­bled AB Sci­ence claims break­out Alzheimer's suc­cess while vTv flops — again

5 years ago
R&D

Al­ny­lam trail­blaz­er Bar­ry Greene jumps to the helm of a strug­gling Sage Ther­a­peu­tics. Can he de­liv­er an­oth­er ...

5 years ago
People

Out of CRISPR pi­o­neer David Li­u's lab comes a small mol­e­cule play tar­get­ing ex­osites — and it's raised a mod­est ...

5 years ago
Financing
Startups

Months in­to boom­ing acute mi­graine launch, Bio­haven chas­es pre­ven­tion with oral CGRP med Nurtec ODT

5 years ago
R&D

Sio Gene Ther­a­pies posts pos­i­tive PhI/II da­ta in rare pe­di­atric dis­ease, the first read­out since its name change

5 years ago
R&D

Gilead’s Dan O’Day pulls the plug on the li­on’s share of their fil­go­tinib col­lab­o­ra­tion as the FDA erects a ...

5 years ago
Deals
FDA+

Ther­mo Fish­er aims to boost its clin­i­cal of­fer­ings with Ger­man ex­pan­sion — in­clud­ing cold chain for the Covid-19 ...

5 years ago
Outsourcing

They thought their gene ther­a­py failed. In­stead, it spawned a med­ical mys­tery

5 years ago
Discovery
In Focus

Take­da’s gene edit­ing part­ner is snapped up for $250M cash as sec­tor con­tin­ues to heat up

5 years ago
Deals

News brief­ing: FDA ap­proves oint­ment for pre­can­cer skin le­sions; Take­da nabs pri­or­i­ty re­view for Shire drug

5 years ago
News Briefing

Mesoblast spins a PhI­II cell ther­a­py miss in heart fail­ure as a win, high­light­ing pos­i­tive mor­tal­i­ty da­ta

5 years ago
R&D

FDA docs give Mod­er­na green light, while spot­light­ing dif­fer­ences with Pfiz­er

5 years ago
FDA+
Coronavirus

Vec­tura leans in­to new role as in­hala­tion CD­MO post-asth­ma flop with plant ex­pan­sion

5 years ago
Outsourcing
Manufacturing

No­var­tis rais­es the temp on Eylea ri­val­ry with head-to-head tri­al win for Beovu in di­a­bet­ic mac­u­lar ede­ma

5 years ago
R&D

Joe Jimenez forges an­oth­er big-mar­ket, small-cash deal, lin­ing up a kid­ney dis­ease drug for his lat­est port­fo­lio ...

5 years ago
Deals

Al­lo­gene, Over­land plot speedy Asia play for off-the-shelf CAR-T with $117M joint ven­ture

5 years ago
Financing
R&D

Sean Harp­er and Beth Sei­den­berg add $500M to their new VC, bet­ting on the LA biotech ecosys­tem

5 years ago
Financing

Covid-19 roundup: US ne­go­ti­at­ing for more dos­es of Pfiz­er vac­cine; Brazil de­lays ef­fi­ca­cy read­out for Sino­vac vac­cine

5 years ago
Coronavirus

Eli Lil­ly picks up gene ther­a­py play­er Pre­vail in deal worth $1B+, mak­ing good on bolt-on pledge from ear­li­er this ...

5 years ago
Deals
Cell/Gene Tx

Bob Nelsen ex­its board and pres­i­dent steps down at Uni­ty as fall­out from the an­ti-ag­ing biotech's PhII miss con­tin­ues

5 years ago
People
Pharma
First page Previous page 765766767768769770771 Next page Last page
A service from the Financial Times